Acadia Reports Phase 2 RADIANT Results for Remlifanserin
SAN DIEGO — September 25, 2026 Acadia Pharmaceuticals Inc. announced topline Phase 2 results from the RADIANT clinical trial...
Acadia Pharmaceuticals
Advertisement
Acadia Pharmaceuticals’ DAYBU Approved in EU for Rett Syndrome
SAN DIEGO, U.S, Aug 28, 2026 Acadia Pharmaceuticals Inc. announced that the European Commission (EC) has granted marketing authorization...
Acadia Secures FDA Fast Track for Alzheimer’s Psychosis Drug
San Diego, California, USA | July 21, 2026 Acadia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA)...
Acadia’s DAYBU Recommended for EU Approval in Rett Syndrome
SAN DIEGO, June 26, 2026 Acadia Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of...
Acadia Expands DAYBUE STIX Access for Rett Syndrome
San Diego, California, USA, April 7, 2026 Broad U.S. Availability Expands Patient Access In a major advancement for rare...
Advertisement
